Citadel Advisors
ALGS icon

Citadel Advisors’s Aligos Therapeutics ALGS Stock Holding History

Citadel Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed -$105 – 14162
2024
Q2 		$105 Buy
12
+4
+50% +$70 ﹤0.01% 14095
2024
Q1 		$196 Buy
+8
New +$159 ﹤0.01% 14397
2023
Q2 		– Sell
-4
Closed -$87 – 14271
2023
Q1 		$87 Hold
4
– – ﹤0.01% 14593
2022
Q4 		$95 Buy
+4
New +$101 ﹤0.01% 14764
2022
Q2 		– Sell
-640
Closed -$34K – 12790
2022
Q1 		$34K Buy
+640
New +$51.3K ﹤0.01% 13032

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors's ALGS Position: Q1 2026 in Review

Citadel Advisors increased its Aligos Therapeutics (ALGS) stake by 4.8% in Q1 2026, buying an estimated $18.8K and bringing the position to 54,311 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #9800.

Citadel Advisors first reported a position in ALGS in Q2 2021 and has held it in 14 quarters since. The position peaked at $483K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Citadel Advisors held 54,311 shares of Aligos Therapeutics worth $404K as of Q1 2026.
  • Citadel Advisors bought 2,477 Aligos Therapeutics shares in Q1 2026, an estimated $18.8K.
  • Aligos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9800 holding.
  • Citadel Advisors first reported a position in Aligos Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Aligos Therapeutics position peaked at $483K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.